2022 Annual Report
As we close another year of unprecedented challenges and achievements, I'm honored to share with you Treatment Action Group's (TAG) 2022 Annual Report.
The ABC for a TB Activist: 1/4/6×24 Campaign and Supportive Diagnostics
On 15 June, 2023, TB Europe Coalition (TBEC) organized a webinar featuring a presentation by Treatment Action Group’s TB Project Officer, David Branigan, on the practical actions advocates can take to promote the adoption and scale up of shorter, safer 1/4/6 regimens for TB prevention and the treatment of drug-sensitive and drug-resistant TB as well as supportive diagnostics.
SMART4TB CONSORTIUM ANNOUNCES COMMUNITY PARTNERS
Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB) is a five-year cooperative agreement made possible by the United States Agency for International Development (USAID), with the assistance of the American people, that aims to transform tuberculosis (TB) prevention and care.
Why Hepatitis C Virus Care Remains Inaccessible
This policy brief explores barriers such as the high-burden among marginalized communities, the complicated diagnostic process, and the difficulties of finding the missing millions of people with HCV in most high-burden countries.
Research in Action Awards 2023
Save the date for Monday, October 19! TAG’s 2023 Research in Action Awards will honor some of the best and brightest activists, scientists, and leaders in the fight to end HIV, tuberculosis, and hepatitis C across the U.S. and around the world.
TAG Remarks Delivered at Multistakeholder Hearings, May, 2023
TAG prepared these remarks to deliver at multistakeholder hearings on health held on May 8 and 9, 2023, at the United Nations Headquarters in New York City.
Nitrosamines and TB Medicines Information Note and Patient FAQs
In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG and IMPAACT4TB project partners have developed several materials to…
The 1/4/6×24 Campaign Coalition Welcomes India’s Rejection of Johnson & Johnson’s Patent Evergreening Tactic
The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.
1/4/6×24 Campaign Videos
All people affected by TB have a right to benefit from scientific progress and to access the best-available short-course regimens for TB prevention and treatment. The 1/4/6x24 Campaign demands that countries and other duty bearers take action to implement the…
For World TB Day, TB Advocates Demand Universal Access to Shorter, Safer TB Regimens
On March 24, World Tuberculosis (TB) Day offers an opportunity to take stock of global progress against the deadliest disease in human history. This year, we face a sobering reality: since the start of the COVID-19 pandemic, rates of TB infection and death are higher than they’ve been since the early 2000s, setting back an already woefully inadequate effort to end the disease.